Australia markets closed

Castle Biosciences, Inc. (CSTL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
21.27+0.20 (+0.95%)
At close: 01:00PM EST
21.37 +0.10 (+0.47%)
After hours: 03:07PM EST

Castle Biosciences, Inc.

505 South Friendswood Drive
Suite 401
Friendswood, TX 77546
United States
866 788 9007
https://castlebiosciences.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full-time employees517

Key executives

NameTitlePayExercisedYear born
Mr. Derek J. MaetzoldFounder, CEO, Pres & Director1.36MN/A1962
Mr. Frank StokesCFO & Treasurer803.01kN/A1970
Ms. Kristen M. Oelschlager R.N., RNChief Operating Officer724.6kN/A1968
Mr. Toby W. JuvenalChief Commercial Officer724.6kN/A1961
Camilla ZuckeroExec. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Alice Bahner IzzoSr. VP of MarketingN/AN/AN/A
Ms. Keli GreenbergVP of HR & Exec. Director of HRN/AN/AN/A
Dr. Robert W. Cook Ph.D.Sr. VP of R&DN/AN/A1972
Mr. Bernhard E. SpiessCompany Sec.N/AN/A1960
Mr. John W. AbbottVP & ControllerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Corporate governance

Castle Biosciences, Inc.’s ISS governance QualityScore as of 1 November 2022 is 9. The pillar scores are Audit: 1; Board: 8; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.